+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Healthcare Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Services (Contract Development, Contract Manufacturing), by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 275 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 5415449
The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030 at a CAGR of 9.2%. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.



Healthcare contract development and manufacturing organization (CDMO) provides outsourcing services to various pharmaceutical industries on a contract basis. An increase in the outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing the operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing pressure on pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development and outsourcing medical devices. Also, the rise in outsourcing of R&D and the growing competency of CDMOs are expected to further contribute to the growing demand for early-stage development CDMOs by life science companies.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development and Manufacturing Organization Market Report Highlights

  • The contract manufacturing segment dominated the market with a revenue share of 73.4% in 2021 due to increasing in the outsourcing of manufacturing services by pharmaceutical and medical device companies.
  • The preclinical /segment is expected to register the highest CAGR of 10.1% in the forecast period due to the rising prevalence of many lifestyle-influenced diseases.
  • North America dominated the healthcare contract development and manufacturing organization market with the largest revenue share of 41.0% in 2021 owing to the presence of a large number of CROs and CMOs in the region.
  • The Asia Pacific is projected to witness the fastest growth during the forecast period owing to low-cost service offered by Asian CROs and CMOs.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Healthcare Contract Development and Manufacturing Organization Market

What is the estimated value of the Global Healthcare Contract Development and Manufacturing Organization Market?

The Global Healthcare Contract Development and Manufacturing Organization Market was estimated to be valued at $232.8 Billion in 2022.

What is the growth rate of the Global Healthcare Contract Development and Manufacturing Organization Market?

The growth rate of the Global Healthcare Contract Development and Manufacturing Organization Market is 9.2%, with an estimated value of $471.0 Billion by 2030.

What is the forecasted size of the Global Healthcare Contract Development and Manufacturing Organization Market?

The Global Healthcare Contract Development and Manufacturing Organization Market is estimated to be worth $471.0 Billion by 2030.

Who are the key companies in the Global Healthcare Contract Development and Manufacturing Organization Market?

Key companies in the Global Healthcare Contract Development and Manufacturing Organization Market include Catalent Inc., Lonza Group Ltd., Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific Inc., Covance Inc., Jabil, Sanmina Corporation and Flex.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Services
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding strategy framework, competitor categorization
1.9.4. Objective 4: Understanding key service scopes to conclude on the market size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Healthcare Contract Development & Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Service
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increasing outsourcing services by pharmaceutical companies
3.4.1.2. Rising investment in R&D
3.4.1.3. Growing pharmaceutical industry
3.4.1.4. Increasing demand for one-stop-shop CDMOs
3.4.2. Market Restraint Analysis
3.4.2.1. Compliance issues while outsourcing
3.4.2.2. Changing scenarios in developing countries
3.4.2.3. Regulatory and legal compliance
3.4.3. Industry Challenges
3.4.3.1. Managing the relationships
3.5. Healthcare CDMO: Market Analysis Tools
3.5.1. Industry Analysis-Porter’s
3.5.1.1. Supplier Power
3.5.1.2. Buyer Power
3.5.1.3. Substitution Threat
3.5.1.4. Threat from new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.3.1. Mergers & Acquisitions
3.5.3.2. Geographic Expansions
3.5.3.3. Partnerships
3.5.3.4. Launch
3.5.3.5. Collaborations
Chapter 4. Healthcare Contract Development & Manufacturing Organization Market: Segment Analysis, by Services, 2018-2030 (USD Billion)
4.1. Definitions & Scope
4.2. Service market share analysis, 2021 & 2030
4.3. Segment Dashboard
4.4. Global Healthcare Contract Development & Manufacturing Organization Market, by services, 2018 to 2030
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Contract Development
4.5.2. Small Molecule
4.5.2.1 Preclinical
4.5.2.1.1 Bioanalysis and DMPK studies
4.5.2.1.2 Toxicology Testing
4.5.2.1.3 Other Preclinical Services
4.5.2.2 Clinical
4.5.2.2.1 Phase I
4.5.2.2.2 Phase II
4.5.2.2.3 Phase III
4.5.2.2.4 Phase IV
4.5.2.3 Laboratory Services
4.5.2.3.1 Bioanalytical Services
4.5.2.3.2 Analytical Services
4.5.3. Large Molecule
4.5.3.1 Cell line development
4.5.3.2 Process development
4.5.3.2.1 Upstream
4.5.3.2.1.1 Microbial
4.5.3.2.1.2 Mammalian
4.5.3.2.1.3 Others
4.5.3.2.2 Downstream
4.5.3.2.2.1 MABs
4.5.3.2.2.2 Recombinant Proteins
4.5.3.2.2.3 Others
4.5.4. Contract Manufacturing
4.5.4.1 Small Molecule
4.5.4.2 Large Molecule
4.5.4.2.1 MABs
4.5.4.2.2 Recombinant Proteins
4.5.4.2.3 Others
4.5.4.3 High Potency API
4.5.4.4 Finished Dose Formulations
4.5.4.4.1 Solid Dose Formulation
4.5.4.4.2 Liquid Dose Formulation
4.5.4.4.3 InjecTable Dose Formulation
4.5.4.5 Medical Device
4.5.4.5.1 Class I
4.5.4.5.2 Class II
4.5.4.5.3 Class III
Chapter 5. Healthcare Contract Development & Manufacturing Organization Market: Regional Market Analysis, by Region, 2018-2030 (USD Billion)
5.1. Definitions & Scope
5.2. Regional Market Share Analysis, 2021 & 2030
5.3. Regional Market Dashboard
5.4. Regional Market Snapshot
5.5. Regional Market Share, 2020
5.6. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030:
5.7. North America
5.7.1. Market estimates and forecast, by country, 2018-2030 (USD Billion)
5.7.2. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.7.3. U.S.
5.7.3.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.7.4. Canada
5.7.4.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8. Europe
5.8.1. Market estimates and forecast, by country, 2018-2030 (USD Billion)
5.8.2. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.3. Germany
5.8.3.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.4. U.K.
5.8.4.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.5. France
5.8.5.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.6. Italy
5.8.6.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.7. Spain
5.8.7.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.8. Netherlands
5.8.8.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.9. Belgium
5.8.9.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.10. Switzerland
5.8.10.1. Market estimates and forecast, by Services, 2016-USD Billion)
5.8.11. Russia
5.8.11.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.8.12. Sweden
5.8.12.1 Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9. Asia Pacific
5.9.1. Market estimates and forecast, by country, 2018-2030 (USD Billion)
5.9.2. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.3. China
5.9.3.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.4. Japan
5.9.4.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.5. India
5.9.5.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.6. Australia
5.9.6.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.7. South Korea
5.9.7.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.8. Malaysia
5.9.8.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.9. New Zealand
5.9.9.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.10. Singapore
5.9.10.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.11. Philippines
5.9.11.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.9.12. Thailand
5.9.12.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10. Latin America
5.10.1. Market estimates and forecast, by country, 2018-2030 (USD Billion)
5.10.2. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10.3. Brazil
5.10.3.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10.4. Mexico
5.10.4.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10.5. Argentina
5.10.5.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10.6. Colombia
5.10.6.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.10.7. Chile
5.10.7.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11. Middle East and Africa
5.11.1. Market estimates and forecast, by country, 2018-2030 (USD Billion)
5.11.2. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11.3. South Africa
5.11.3.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11.4. Saudi Arabia
5.11.4.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11.5. UAE
5.11.5.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11.6. Israel
5.11.6.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
5.11.7. Egypt
5.11.7.1. Market estimates and forecast, by Services, 2018-2030 (USD Billion)
Chapter 6. Healthcare Contract Development & Manufacturing Organization Market-Competitive Analysis
6.1. Key companies profiled
6.1.1. Catalent Inc.
6.1.1.1. Company Overview
6.1.1.2. Financial Performance
6.1.1.3. Product Benchmarking
6.1.1.4. Strategic Initiatives
6.1.2. Lonza Group Ltd.
6.1.2.1. Company Overview
6.1.2.2. Financial Performance
6.1.2.3. Product Benchmarking
6.1.2.4. Strategic Initiatives
6.1.3. Recipharm AB
6.1.3.1. Company Overview
6.1.3.2. Financial Performance
6.1.3.3. Product Benchmarking
6.1.3.4. Strategic Initiatives
6.1.4. Siegfried Holding AG
6.1.4.1. Company Overview
6.1.4.2. Financial Performance
6.1.4.3. Product Benchmarking
6.1.4.4. Strategic Initiatives
6.1.5. Thermo Fisher Scientific Inc.
6.1.5.1. Company Overview
6.1.5.2. Financial Performance
6.1.5.3. Product Benchmarking
6.1.5.4. Strategic Initiatives
6.1.6. Covance Inc.
6.1.6.1. Company Overview
6.1.6.2. Financial Performance
6.1.6.3. Product Benchmarking
6.1.6.4. Strategic Initiatives
6.1.7. Jabil
6.1.7.1. Company Overview
6.1.7.2. Financial Performance
6.1.7.3. Product Benchmarking
6.1.7.4. Strategic Initiatives
6.1.8. Sanmina Corporation
6.1.8.1. Company Overview
6.1.8.2. Financial Performance
6.1.8.3. Product Benchmarking
6.1.8.4. Strategic Initiatives
6.1.9. IQVIA Holdings Inc.
6.1.9.1. Company Overview
6.1.9.2. Financial Performance
6.1.9.3. Product Benchmarking
6.1.9.4. Strategic Initiatives
6.1.10. Flex
6.1.10.1. Company Overview
6.1.10.2. Financial Performance
6.1.10.3. Product Benchmarking
6.1.10.4. Strategic Initiatives

Companies Mentioned

  • Catalent Inc.
  • Lonza Group Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Covance Inc.
  • Jabil
  • Sanmina Corporation
  • IQVIA Holdings Inc.
  • Flex

Methodology

Loading
LOADING...